CTI BioPharma Corp. Forecasted to Post Q3 2017 Earnings of ($0.32) Per Share (CTIC)
CTI BioPharma Corp. (NASDAQ:CTIC) – Jefferies Group issued their Q3 2017 earnings per share estimates for shares of CTI BioPharma Corp. in a report issued on Tuesday. Jefferies Group analyst M. Andrews anticipates that the biopharmaceutical company will post earnings per share of ($0.32) for the quarter. Jefferies Group has a “Buy” rating and a $7.50 price objective on the stock. Jefferies Group also issued estimates for CTI BioPharma Corp.’s Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.26) EPS, Q1 2018 earnings at ($0.32) EPS, Q2 2018 earnings at ($0.31) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($1.87) EPS, FY2019 earnings at ($0.71) EPS, FY2020 earnings at ($0.25) EPS and FY2021 earnings at $0.26 EPS.
CTI BioPharma Corp. (NASDAQ:CTIC) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The firm had revenue of $22.23 million for the quarter. ILLEGAL ACTIVITY NOTICE: “CTI BioPharma Corp. Forecasted to Post Q3 2017 Earnings of ($0.32) Per Share (CTIC)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/cti-biopharma-corp-forecasted-to-post-q3-2017-earnings-of-0-32-per-share-ctic.html.
CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.29 on Thursday. The firm’s market capitalization is $104.38 million. The firm’s 50-day moving average price is $3.34 and its 200-day moving average price is $3.77. CTI BioPharma Corp. has a 1-year low of $0.36 and a 1-year high of $6.48.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC bought a new stake in shares of CTI BioPharma Corp. during the 2nd quarter worth $7,561,000. Nine Chapters Capital Management LLC boosted its holdings in CTI BioPharma Corp. by 152.9% in the 1st quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 26,300 shares during the period. Acadian Asset Management LLC bought a new stake in CTI BioPharma Corp. in the 1st quarter valued at $181,000. WASHINGTON TRUST Co bought a new stake in CTI BioPharma Corp. in the 2nd quarter valued at $104,000. Finally, Segantii Capital Management Ltd bought a new stake in CTI BioPharma Corp. in the 1st quarter valued at $102,000. 42.87% of the stock is owned by institutional investors and hedge funds.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.